Literature DB >> 25346241

Preparation and Evaluation of 99mTc-labeled anti-CD11b Antibody Targeting Inflammatory Microenvironment for Colon Cancer Imaging.

Dengfeng Cheng1,2, Weihong Zou3, Xiao Li1,2, Yan Xiu1,2, Hui Tan1,2, Hongcheng Shi1,2, Xiangdong Yang4.   

Abstract

CD11b, an active constituent of innate immune response highly expressed in myeloid-derived suppressor cells (MDSCs), can be used as a marker of inflammatory microenvironment, particularly in tumor tissues. In this research, we aimed to fabricate a (99m)Tc-labeled anti-CD11b antibody as a probe for CD11b(+) myeloid cells in colon cancer imaging with single-photon emission computed tomography (SPECT). In situ murine colon tumor model was established in histidine decarboxylase knockout (Hdc(-/-)) mice by chemicals induction. (99m)Tc-labeled anti-CD11b was obtained with labeling yields of over 30% and radiochemical purity of over 95%. Micro-SPECT/CT scans were performed at 6 h post injection to investigate biodistributions and targeting of the probe. In situ colonic neoplasma as small as 3 mm diameters was clearly identified by imaging; after dissection of the animal, anti-CD11b immunofluorescence staining was performed to identify infiltration of CD11b+ MDSCs in microenvironment of colonic neoplasms. In addition, the images displayed intense signal from bone marrow and spleen, which indicated the origin and migration of CD11b(+) MDSCs in vivo, and these results were further proved by flow cytometry analysis. Therefore, (99m)Tc-labeled anti-CD11b SPECT displayed the potential to facilitate the diagnosis of colon tumor in very early stage via detection of inflammatory microenvironment.
© 2014 John Wiley & Sons A/S.

Entities:  

Keywords:  SPECT; Tc-99m; anti-CD11b antibody; colon cancer; inflammation; myeloid-derived suppressor cells

Mesh:

Substances:

Year:  2014        PMID: 25346241     DOI: 10.1111/cbdd.12459

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  4 in total

Review 1.  In vivo imaging with antibodies and engineered fragments.

Authors:  Amanda C Freise; Anna M Wu
Journal:  Mol Immunol       Date:  2015-04-28       Impact factor: 4.407

Review 2.  Noninvasive Imaging of Cancer Immunotherapy.

Authors:  Omar Abousaway; Taha Rakhshandehroo; Annick D Van den Abbeele; Moritz F Kircher; Mohammad Rashidian
Journal:  Nanotheranostics       Date:  2021-01-01

Review 3.  Molecular Immune Targeted Imaging of Tumor Microenvironment.

Authors:  Taha Rakhshandehroo; Bryan Ronain Smith; Hannah J Glockner; Mohammad Rashidian; Neeta Pandit-Taskar
Journal:  Nanotheranostics       Date:  2022-02-15

Review 4.  Molecular imaging biomarkers for immune checkpoint inhibitor therapy.

Authors:  Pim P van de Donk; Laura Kist de Ruijter; Marjolijn N Lub-de Hooge; Adrienne H Brouwers; Anthonie J van der Wekken; Sjoukje F Oosting; Rudolf Sn Fehrmann; Derk Jan A de Groot; Elisabeth Ge de Vries
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.